Vertex Reports Phase 1/2 Stem-Cell Islet Therapy Success, Pauses Dosing for Manufacturing Analysis
VRTX•Vertex’s Phase 1/2 stem-cell-derived islet therapy restored insulin production in all 12 treated patients, marking full trial response. The company has temporarily paused completion of dosing to conduct an internal manufacturing analysis before advancing to subsequent trial stages.
1. Phase 1/2 Trial Results
Vertex reported that all 12 patients in the Phase 1/2 portion of its stem-cell-derived islet therapy trial achieved restored insulin production, demonstrating consistent beta cell functionality without serious safety concerns during the initial dosing period.
2. Manufacturing Analysis Delay
The company has temporarily postponed completion of dosing to perform an internal manufacturing analysis aimed at validating and optimizing cell production processes, a step intended to ensure scalable, GMP-compliant supply before moving into later-stage clinical studies.
